EDAP's MRI (magnetic resonance imaging)-guided HIFU (high intensity focused ultrasound) used for breast cancer:
This article was originally published in Clinica
Executive Summary
French company EDAP TMS has reported that its MRI-guided ultrasound treatment has been used to treat breast cancer for the first time in Europe. Doctors in Germany used the company's MRI-guided high intensity focused ultrasound (HIFU) system to treat the first participant of an 18-patient trial of the product. The system allows doctors to deliver HIFU to a focal point where malignant cells are heated and destroyed. The procedure lasts around three hours, including 80 minutes for the treatment itself. Vaulx-en-Velin-based EDAP already markets its HIFU-based treatment for prostate cancer, Ablatherm, in Europe
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.